Basic overview of current immunotherapy approaches in urologic malignancy : The status of cancer vaccine therapies in urologyDRAKE, Charles G.Urologic oncology. 2006, Vol 24, Num 5, pp 413-418, issn 1078-1439, 6 p.Article

Immunotherapy for metastatic prostate cancerDRAKE, Charles G.Urologic oncology. 2008, Vol 26, Num 4, pp 438-444, issn 1078-1439, 7 p.Conference Paper

Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic MelanomaLIPSON, Evan J; DRAKE, Charles G.Clinical cancer research (Print). 2011, Vol 17, Num 22, pp 6958-6962, issn 1078-0432, 5 p.Article

Molecular Pathways: Coexpression of Immune Checkpoint Molecules: Signaling Pathways and Implications for Cancer ImmunotherapyNIRSCHL, Christopher J; DRAKE, Charles G.Clinical cancer research (Print). 2013, Vol 19, Num 18, pp 4917-4924, issn 1078-0432, 8 p.Article

Tumor immunology: towards a paradigm of reciprocal researchDRAKE, Charles G; PARDOLL, Drew M.Seminars in cancer biology. 2002, Vol 12, Num 1, pp 73-80, issn 1044-579XArticle

Immunotherapy for Brain Cancer: Recent Progress and Future PromiseJACKSON, Christopher M; LIM, Michael; DRAKE, Charles G et al.Clinical cancer research (Print). 2014, Vol 20, Num 14, pp 3651-3659, issn 1078-0432, 9 p.Article

Immunotherapy for Prostate Cancer: Recent Advances, Lessons Learned, and Areas for Further Research : Therapeutic Advances in Prostate CancerGULLEY, James L; DRAKE, Charles G.Clinical cancer research (Print). 2011, Vol 17, Num 12, pp 3884-3891, issn 1078-0432, 8 p.Article

LAG-3 in Cancer ImmunotherapyGOLDBERG, Monica V; DRAKE, Charles G.Current Topics in Microbiology and Immunology. 2011, Vol 344, pp 269-278, issn 0070-217X, 10 p.Article

Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccinesGANG ZHOU; DRAKE, Charles G; LEVITSKY, Hyam I et al.Blood. 2006, Vol 107, Num 2, pp 628-636, issn 0006-4971, 9 p.Article

Enhancement of the T-cell Armamentarium as a Cell-Based Therapy for Prostate CancerBRENNEN, W. Nathaniel; DRAKE, Charles G; ISAACS, John T et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 13, pp 3390-3395, issn 0008-5472, 6 p.Article

Complete Biochemical (Prostate-specific Antigen) Response to Sipuleucel-T With Enzalutamide in Castration-resistant Prostate Cancer: A Case Report With Implications for Future ResearchGRAFF, Julie N; DRAKE, Charles G; BEER, Tomasz M et al.Urology (Ridgewood, NJ). 2013, Vol 81, Num 2, pp 381-383, issn 0090-4295, 3 p.Article

Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention TrialGUREL, Bora; LUCIA, M. Scott; PESKOE, Sarah B et al.Cancer epidemiology, biomarkers & prevention. 2014, Vol 23, Num 5, pp 847-856, issn 1055-9965, 10 p.Article

Association of ILI0 and Other Immune Response-and Obesity-Related Genes With Prostate Cancer in CLUE IIWANG, Ming-Hsi; HELZLSOUER, Kathy J; PLATZ, Elizabeth A et al.The Prostate. 2009, Vol 69, Num 8, pp 874-885, issn 0270-4137, 12 p.Article

Safety, Activity, and Immune Correlates of Anti―PD-1 Antibody in CancerTOPALIAN, Suzanne L; HODI, F. Stephen; LEMING, Philip D et al.The New England journal of medicine. 2012, Vol 366, Num 26, pp 2443-2454, issn 0028-4793, 12 p.Article

Prostate Cancer ImmunotherapyMAY, Kenneth F; GULLEY, James L; DRAKE, Charles G et al.Clinical cancer research (Print). 2011, Vol 17, Num 16, pp 5233-5238, issn 1078-0432, 6 p.Article

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cellsGOLDBERG, Monica V; MARIS, Charles H; BROCKSTEDT, Dirk G et al.Blood. 2007, Vol 110, Num 1, pp 186-192, issn 0006-4971, 7 p.Article

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesBRAHMER, Julie R; DRAKE, Charles G; GILSON, Marta M et al.Journal of clinical oncology. 2010, Vol 28, Num 19, pp 3167-3175, issn 0732-183X, 9 p.Article

Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer ModelWADA, Satoshi; YOSHIMURA, Kiyoshi; ANDERS, Robert et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 10, pp 4309-4318, issn 0008-5472, 10 p.Article

Eos Mediates Foxp3-Dependent Gene Silencing in CD4⁺ Regulatory T CellsFAN PAN; HONG YU; DRAKE, Charles G et al.Science (Washington, D.C.). 2009, Vol 325, Num 5944, pp 1142-1146, issn 0036-8075, 5 p.Article

Cancer Immunotherapy Highlights from the 2014 ASCO MeetingHARSHMAN, Lauren C; DRAKE, Charles G; WARGO, Jennifer A et al.Cancer immunology research (Print). 2014, Vol 2, Num 8, pp 714-719, issn 2326-6066, 6 p.Article

Variation in IL10 and Other Genes Involved in the Immune Response and in Oxidation and Prostate Cancer RecurrenceDLUZNIEWSKI, Paul J; WANG, Ming-Hsi; ISAACS, William B et al.Cancer epidemiology, biomarkers & prevention. 2012, Vol 21, Num 10, pp 1774-1782, issn 1055-9965, 9 p.Article

Radiotherapy Augments the Immune Response to Prostate Cancer in aTime-Dependent MannerHARRIS, Timothy J; HIPKISS, Edward L; DEWEESE, Theodore L et al.The Prostate. 2008, Vol 68, Num 12, pp 1319-1329, issn 0270-4137, 11 p.Article

Epithelial architectural destruction is necessary for bone marrow derived cell contribution to regenerating prostate epitheliumPALAPATTU, Ganesh S; MEEKER, Alan; HARRIS, Timothy et al.The Journal of urology. 2006, Vol 176, Num 2, pp 813-818, issn 0022-5347, 6 p.Article

Giant cavernous carotid aneurysms: Clinical presentation in fifty-seven casesHAHN, Cecil D; NICOLLE, David A; LOWNIE, Stephen P et al.Journal of neuro-ophthalmology. 2000, Vol 20, Num 4, pp 253-258, issn 1070-8022Article

Anti-Tumor Effects of Endogenous Prostate Cancer-Specific CD8 T Cells in a Murine TCR Transgenic ModelBRUNO, Tullia C; ROTHWELL, Cristin; GROSSO, Joseph F et al.The Prostate. 2012, Vol 72, Num 5, pp 514-522, issn 0270-4137, 9 p.Article